PCa Immunotherapy Combo Promising
SAN DIEGO—Dutch researchers have reported preliminary success with a combination of the GVAX immunotherapeutic vaccine and ipilimumab (MDX-010, Medarex, Inc) in patients with metastatic hormone-refractory prostate cancer.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.